## Hernexeos (zongertinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	_ MEMBER'S FIRST I	MEMBER'S FIRST NAME:				
	view (e.g., chart notes or	lab data, to support th	r. Attach any additional documentation authorization request). Information				
			☐ URGEN				
MEMBER INFORMATIO	N						
LAST NAME:		FIRST NAME:					
PHONE NUMBER:		DATE OF BIRTH:					
STREET ADDRESS:							
CITY:		STATE:	ZIP CODE:				
PATIENT INSURANCE	D NUMBER:						
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG):	ALLERGIES:				
IF YOU ARE NOT THE PATIENT'S AUTHORIZE	ZATION FORM WITH TH METHERAPEUTICS.COM	IIS REQUEST WHICH M/NOPP	I CAN BE FOUND AT THE				
<b>AUTHORIZED REPRESE</b>							
PRESCRIBER INFORM	ATION						
LAST NAME:		FIRST NAME:					
PRESCRIBER SPECIAL	.TY:	EMAIL ADDRES	EMAIL ADDRESS:				
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:				
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:				
STREET ADDRESS:							
CITY:		STATE:	STATE: ZIP CODE:				
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:				
		1					
MEDICATION OR MEDI	CAL DISPENSING INFO	RMATION					
MEDICATION NAME:							
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFI	QUANTITY:				
☐ NEW THERAPY	RENEWAL IF	RENEWAL: DATE T	=				
DURATION OF THERAF	Y (SPECIFIC DATES):						
Continued on next page	Continued on next page						

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



## Hernexeos (zongertinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST	NAME:
1. HAS THE PATIENT TRIED AN	OTHER MEDICATIONS FOR THIS	S CONDITION?
YES (if yes, complete below)		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Non-small cell lung cancer ☐ Other diagnosis:	ICD-10 Code(s):	
3. REQUIRED CLINICAL INFORM TO SUPPORT A PRIOR AUTHOR		ELEVANT CLINICAL INFORMATION
Initial Request:  Does patient have a diagnosis of cancer (NSCLC)?  Yes No  Does patient's tumors have HER No Please submit documentation  Has patient been previously treatherapy? Yes No Please submit diagnosis of the previously treatherapy? Remember 1 Yes No Please submit diagnosis of the previously treatherapy? Remember 1 Yes No Please submit diagnosis of the previously treatherapy? Remember 1 Yes No Please submit diagnosis of the previously treatherapy? Remember 1 Yes No Please submit diagnosis of the previously treatherapy? Remember 1 Yes No Please submit diagnosis of the previously treatherapy? Remember 2 Yes No Please submit documentation and the previously treatherapy and the previously treatherap	2 (ERBB2) tyrosine kinase domain n. ted in the advanced/metastatic se submit documentation.	equamous non-small cell lung  n activating mutations?  Yes  tting with at least one prior  ne kinase inhibitor (TKI) or HER2- ubmit documentation.
Are there any other comments, conformation the physician feels is	liagnoses, symptoms, medication s important to this review?	s tried or failed, and/or any other
required information is received.	is are covered on all plans. This req	•
understand that the Health Plan, in	ation provided is true and accurate to surer, Medical Group or its designee cessary to verify the accuracy of the	s may perform a routine audit and
Prescriber Signature or Electron	ic ID Varification:	Date:

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.25 CAT009



## Hernexeos (zongertinib) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBED'S FIRST NAME.

MEMBER O LAGI NAME.			
	CONFIDENTIALITY NOTICE: The documents acc	companying this transmission cont	tain confidential health
	CONTIDENTIALITY NOTICE: THE decaments does	sompanying this transmission com	tain cominacina nealth

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO:** 800-424-7640

**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909



MEMBED'S LAST NAME.